Jason Hoitt is Chief Patient Officer at Stoke Therapeutics, Inc. (STOK). They have made 5 open-market trades across 3 companies since 2019, most recently 2026-03-18.
CIK 0001762572
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $24K since 2020, against 4 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| STOK | 12,955 | $314K |
| DOVA | 9,970 | $280K |
| PRVB | 4,500 | $112K |
| Total | $705K |
Shares reported on the most recent Form 4, priced at the 2026-03-19 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| STOK | SELL | 2026-03-17 | 2026-03-19 | $32.14 | $238K | -4.5% | +6.9% | -11.4% |
| PRVB | SELL · 10b5-1 | 2023-02-10 | 2023-02-14 | $10.00 | $45K | -16.3% | +143.4% | N/A |
| PRVB | BUY | 2020-03-19 | 2020-03-20 | $5.43 | $24K | +17.2% | +69.3% | +136.4% |
| DOVA | SELL | 2019-09-30 | 2019-10-02 | $28.00 | $67K | +0.2% | +0.7% | N/A |
| DOVA | SELL | 2019-07-15 | 2019-07-16 | $15.26 | $116K | -3.4% | -7.8% | +74.9% |
| DOVA | SELL | 2019-06-28 | 2019-07-02 | $13.81 | $33K | -2.7% | -4.4% | +69.4% |
| DOVA | SELL · 10b5-1 | 2019-04-08 | 2019-04-10 | $8.77 | $21K | -0.7% | +27.0% | +93.7% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.